PedAM
Pediatric Disease Annotations & Medicines
| Disease | vascular disease |
| Phenotype | |diabetes |
| Sentences | 529 |
| PubMedID- 22436702 | In patients with diabetes, the major cause of death is macrovascular disease [2,3], and in individuals with type 2 diabetes, the main etiology for up to 75% of the mortality is atherosclerotic cardiovascular disease [4]. |
| PubMedID- 22809064 | Both ra and diabetes increase the risk of cardiovascular disease (cvd), yet understanding of how comorbid ra impacts the receipt of guideline-based diabetes care is limited. |
| PubMedID- 22419928 | Cardiovascular disease in diabetes mellitus is multi-factorial and risk factors include hypertension, dyslipidaemia, insulin resistance and central obesity [8]. |
| PubMedID- 22525426 | The prevalence of atherosclerotic cardiovascular disease is higher in patients with type 2 diabetes, a disorder characterized by hyperinsulinemia and insulin resistance. |
| PubMedID- 26252223 | Dyslipidemia is a strong risk factor for cardiovascular disease among patients with type 2 diabetes (t2d). |
| PubMedID- 23144974 | In univariate analysis, age, diabetes mellitus, previous history of cardiovascular disease, smoking, lipid-lowering therapy, serum albumin, ipth, and hs-crp concentrations were significantly associated with the presence of aoac at baseline. |
| PubMedID- 20822519 | Contradictory results have also been published regarding the role of fetuin-a in macrovascular disease and patients with type 2 diabetes [12-14]. |
| PubMedID- 25708055 | This study aimed to assess the effects of active and passive smoking exposure on the development of cardiovascular disease in patients with type 2 diabetes mellitus. |
| PubMedID- 23844096 | The correlations between tat and patency remained significant after adjustment for age, diabetes, smoking, history of cardiovascular disease, and number of days since avf creation in a multivariate linear regression model. |
| PubMedID- 22748161 | Many classic and novel risk factors have been investigated to determine whether they explain the higher risk of cardiovascular disease among people with diabetes [4-6]. |
| PubMedID- 22035298 | However, limited information exists with regard to cardiovascular disease risk in patients with diabetes and renal dysfunction, particularly after ami. |
| PubMedID- 25658588 | Abbreviations: bmi, body mass index; egfr, estimated glomerular filtration rate; proteinuria, proteinuria positive; dm, diabetes mellitus; cvd, history of cardiovascular disease; hyperuricemia, history of hyperuricemia including gout; alcohol, daily alcohol consumption; exercise, having regular exercise. |
| PubMedID- 21632491 | Sensitive cardiac troponin t assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the women's health study. |
| PubMedID- 23243415 | diabetes is associated with increased cardiovascular disease, but the underlying cellular and molecular mechanisms are poorly understood. |
| PubMedID- 20609967 | Conversely, any preferential diagnosis of vascular disease in people with diabetes would have tended to overestimate hrs. |
| PubMedID- 26426904 | The nature of comorbid cardiovascular disease, concordant with diabetes, probably explains its augmenting effect observed for sbp. |
| PubMedID- 23938049 | Dyslipidemia, undesirable changes in vascular endothelial and smooth muscle cells, lipid peroxidation especially oxidized low-density lipoprotein particles, oxidative damage and increased inflammatory mediators including chemokines and cytokines, hyper-coagulation and platelet activation have been considered as the main metabolic abnormalities in diabetes mellitus leading to cardiovascular disease [54]. |
| PubMedID- 21854817 | Subjects with diabetes mellitus, evidence of myocardial infarction or cerebrovascular disease were excluded from the study. |
| PubMedID- 25285280 | [45678] approximately, 80% of deaths in patients with diabetes are attributable to cardiovascular disease (cvd). |
| PubMedID- 20836897 | Multiple and complex pathways promote the deleterious effects of hyperglycemia in diabetes, ultimately leading to micro- and macrovascular disease. |
| PubMedID- 25149070 | Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the fenofibrate intervention and event lowering in diabetes (field) study. |
| PubMedID- 20591087 | diabetes leads to premature cardiovascular disease and is regarded by many as the most common etiological factor for chronic kidney disease. |
| PubMedID- 22373102 | Percutaneous therapy for limb-threatening lower extremity vascular disease with or without diabetes has no exception, with primary patency rates at 36 months of 46.5% and 60.9%. |
| PubMedID- 24308487 | Prevalence of cardiovascular disease in participants with and without diabetes, born in iraq or sweden. |
| PubMedID- 23798924 | [1112] positive results in different clinical trials have strengthen the value and acceptance of hscrp, which is recommended as a predictive laboratory marker for cardiovascular disease risk in patients with diabetes mellitus. |
| PubMedID- 21437092 | Proactive was a prospective, randomized controlled trial that included 5,238 patients with type 2 diabetes who had evidence of macrovascular disease. |
| PubMedID- 24443675 | Brain abnormalities such as white matter lesions (wmls) are not only linked to cerebrovascular disease, but also with normal aging, diabetes and other conditions increasing the risk for cerebrovascular pathologies. |
| PubMedID- 25799396 | When clinical characteristics (age, gender, smoking, hypertension, diabetes, activity of disease, cardiovascular disease, obesity, menopausal status) between dyslipidemic and non-dyslipidemic cs patients were compared, to explain shorter tl in dyslipidemic cs patients, the former were older (dyslipidemic 53±11.7 years vs non dyslipidemic 45±12.7 years, p < 0.05) and more frequently obese (49% vs. 34% in non-dyslipidemic cs patients, p < 0.05); these differences persisted after adjustment for bmi and age (7313±1210 vs 7873±1182 bp, p <0.05). |
| PubMedID- 23393213 | Second, the presence of microvascular diseases commonly present in patients with diabetes mellitus may contribute to progressive microvascular ischemia or microembolization that can be readily detectable by highly sensitive ctni assay. |
| PubMedID- 24147047 | To stratify the subjects, comorbid conditions and other risk factors such as congestive heart failure, hypertension, age ≥75, diabetes, history of stroke, vascular disease, age 65–74, and sex category were taken into account according to the cha2ds2-vasc or chads2 scheme criteria [5,11]. |
| PubMedID- 22523674 | As with increasing adiposity in aging and loss of muscle mass, the insulin-mediated glucose uptake and tg disposal in the skeletal muscle of elderly persons is reduced and the maintenance of a large muscle mass can contribute to the prevention of type 2 diabetes, which is associated with cardiovascular disease. |
| PubMedID- 22093212 | Background: more intensive glycemic control reduces the risk of microvascular disease in patients with diabetes mellitus but has not been proven to reduce the risk of macrovascular events such as myocardial infarction and stroke. |
| PubMedID- 23082138 | Model ii: adjustment for the covariates mentioned above plus diabetes, history of hypertension, previous cardiovascular disease, and medication treatment. |
| PubMedID- 20380625 | Type 2 diabetes (t2d) is associated with increased cardiovascular disease and mortality. |
| PubMedID- 25733983 | We attempted to evaluate the risk of ischemic stroke preferentially, because incidence rate for ischemic stroke was greater than any other cardiovascular diseases among patients with diabetes [8]. |
| PubMedID- 24250240 | However, the action to control cardiovascular disease in diabetes (accord) study revealed an increased cardiovascular mortality rate in intensively treated patients, as well as a minimal benefit to the burden of intensive treatment.3,4 some argue that there is a greater risk than benefit to tight control among geriatric patients.5 the american diabetes association (ada) altered its target glucose goals for the elderly in 2013 to recommend that practitioners individualize therapy.6 yet, how to accomplish this goal in a busy primary care office remains elusive for most practitioners. |
| PubMedID- 22108456 | However, the underlying mechanisms linking type 2 diabetes with cardiovascular disease remain poorly understood. |
| PubMedID- 23832457 | We present the case of a 61-year-old male patient with concomitant chronic kidney disease (ckd stage iii k/doqi) and diabetes complicated by severe multi-vascular disease, who developed acute kidney damage probably due to the simultaneously exposure to intravascular contrast media and cholesterol crystal embolism. |
| PubMedID- 22647032 | The pathophysiology of vascular disease in diabetes involves abnormalities in endothelial cells, vascular smooth muscle cells, and monocytes. |
| PubMedID- 20334577 | Patients and methods: in 200 normoalbuminuric (<30 mg/24 h) hts 55-75 years old, without diabetes and history of coronary and cerebrovascular diseases, pearson's correlation assess the relationship between rsgfr and egfr. |
| PubMedID- 23035799 | There are very few studies that have reported factors associated with cardiovascular disease control in patients with diabetes, as opposed to adults in general, irrespective of diabetes status. |
| PubMedID- 25847351 | Recent epidemiological evidence has also shown a direct association between cognitive decline and markers of symptomatic and asymptomatic vascular disease in people with type 2 diabetes [5]. |
| PubMedID- 22230215 | The mean egfrs, adjusted for age (continuous variable), sex, comorbid hypertension and diabetes mellitus, and history of cardiovascular diseases by multiple linear regression models, were compared between genotypes using the homozygous for the major allele as the reference. |
| PubMedID- 24500563 | Despite the profound clinical importance of vascular disease in patients with diabetes mellitus, our understanding of the relative contributions of insulin resistance and hyperglycemia to atherogenesis is not complete. |
| PubMedID- 24367528 | Around half of all deaths in those with type 2 diabetes are due to cardiovascular disease [18]. |
| PubMedID- 25881261 | Foot ischemia in patients with diabetes may be attributed to atherosclerotic macrovascular disease and additional microcirculatory dysfunction. |
| PubMedID- 26381503 | Erythropoiesis stimulating agent (esa) treatments targeting mild anemia (10-12 g/dl) can decrease the risk of occurrence of cardiovascular disease (cvd) in patients with hypertension, diabetes mellitus and congestive heart failure. |
| PubMedID- 21735134 | We prospectively studied 2,277 cardiac patients, and the results show high congruence between the markov model and the ph model; both evidence that diabetes, history of stroke, peripheral vascular disease and smoking significantly increase hazard rate and reduce survival time. |
| PubMedID- 24396666 | Other recent reports showed that variations in long-term glycemia, defined as a1c variability, were powerful independent predictors for diabetic microvascular complications and even for cardiovascular disease (cvd) events in patients with type 1 diabetes [12,20]. |
| PubMedID- 23849306 | Table 3.relationship between plasma fgf-23 concentrations and change in left ventricular ejection fraction during follow-up in chronic dialysis patients.modelfgf-23 tertiles (ru/ml) difference (95% ci)log10 fgf-23 difference (95% ci)≤ 1,9661,967 – 11,492> 11,492unadjusted0.0 (ref)–1.0 (–7.2 to 5.2)–6.7 (–13.1 to –0.33)–4.3 (–9.3 to 0.66)model 10.0 (ref)0.13 (–6.6 to 6.9)–8.0 (–15.5 to –0.53)–6.5 (–11.3 to –1.73)model 20.0 (ref)0.12 (–6.8 to 7.0)–8.4 (–16.2 to –0.62)–7.2 (–12.3 to –2.1)model 1: adjusted for age, gender, race, diabetes, hypertension, history of cardiovascular disease, body mass index, systolic blood pressure, serum albumin, hemoglobin, phosphorus, plasma 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d. model 2: adjusted for covariates in model 1 plus use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers and β-blockers. |